Atopic Dermatitis News and Research

RSS
Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.
Autumn-born children prone to asthma

Autumn-born children prone to asthma

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

New evidence-based guidelines for diagnosis and assessment of atopic dermatitis

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

Icahn School of Medicine receives $2.7M to investigate narrow pathway targeted immune therapy

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Dermalogix awarded SBIR Phase II grant to develop topical drug candidate for atopic dermatitis

Index predicts asthma in high-risk preschool children

Index predicts asthma in high-risk preschool children

Gene mutations responsible for persistent AD in African American children

Gene mutations responsible for persistent AD in African American children

New finding could help lead to better treatments for eczema

New finding could help lead to better treatments for eczema

Dermatologists provide list of specific treatments, procedures not required for medical care

Dermatologists provide list of specific treatments, procedures not required for medical care

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Asthma infection risk ‘goes beyond the airways’

Asthma infection risk ‘goes beyond the airways’

New picture of interaction between nervous & immune systems could lead to novel therapies

New picture of interaction between nervous & immune systems could lead to novel therapies

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Study: Structural defect in skin cells can contribute to allergy development

Study: Structural defect in skin cells can contribute to allergy development

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis